Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels(UCLouvain), Ezra E.W. Cohen(University of California San Diego), Jan B. Vermorken(Antwerp University Hospital), J. Guigay(Centre Antoine Lacassagne), Makoto Tahara(National Cancer Center Hospital East), Jérôme Fayette(Hospices Civils de Lyon), Thomas Gauler, Lisa Licitra(University of Milan), Luciano de Souza Viana(Hospital de Câncer de Barretos), Ulrich Keilholz(Berliner Hochschule für Technik), Robert I. Haddad(Dana-Farber Cancer Institute), Gilberto de Castro(Twitter (United States)), Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), E. Ehrnrooth(Boehringer Ingelheim (Germany)), Francesco Caponigro, Joseph M del Campo(Vall d'Hebron Hospital Universitari), Paul M. Clément(KU Leuven), Juan J. Grau(Hospital Clínic de Barcelona), Xiuyu Julie Cong(Boehringer Ingelheim (United States))
Cited by 391
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|652